Literature DB >> 19390308

Histopathology of Hodgkin's lymphoma.

Franziska C Eberle1, Haresh Mani, Elaine S Jaffe.   

Abstract

In the last few years, there has been a greater understanding of the spectrum and biology of Hodgkin's lymphoma. In standard texts, Hodgkin's lymphoma is classified as 2 distinct entities, namely nodular lymphocyte predominant Hodgkin's lymphoma and classical Hodgkin's lymphoma. However, recent evidence suggests that classical Hodgkin's lymphoma is not a single disease. Although the mixed cellularity and lymphocyte-depleted subtypes may be part of a biologic continuum, the nodular sclerosis subtype has a distinct epidemiology, clinical presentation, and histology. Nodular sclerosis Hodgkin's lymphoma, particularly those cases presenting with mediastinal disease, also seems related to primary mediastinal B-cell lymphoma. As Hodgkin's lymphoma is a B-cell neoplasm, there is also a better appreciation today of cases that may be borderline with conventional B-cell lymphomas. We present an update on the histopathological features of Hodgkin's lymphoma and the immunohistochemical tools available for diagnosis in the clinical setting.

Entities:  

Mesh:

Year:  2009        PMID: 19390308     DOI: 10.1097/PPO.0b013e31819e31cf

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  15 in total

1.  Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT.

Authors:  Ulrike Bacher; Mascha Binder
Journal:  Ann Transl Med       Date:  2016-10

2.  Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adulthood.

Authors:  Casey Crump; Kristina Sundquist; Weiva Sieh; Marilyn A Winkleby; Jan Sundquist
Journal:  Am J Epidemiol       Date:  2012-11-21       Impact factor: 4.897

3.  Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Franziska C Eberle; Jaime Rodriguez-Canales; Lai Wei; Jeffrey C Hanson; J Keith Killian; Hong-Wei Sun; Lisa G Adams; Stephen M Hewitt; Wyndham H Wilson; Stefania Pittaluga; Paul S Meltzer; Louis M Staudt; Michael R Emmert-Buck; Elaine S Jaffe
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

4.  Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival.

Authors:  Stella M Ranuncolo; Stefania Pittaluga; Moses O Evbuomwan; Elaine S Jaffe; Brian A Lewis
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

Review 5.  [Mediastinal lymphomas].

Authors:  S Rauthe; A Rosenwald
Journal:  Pathologe       Date:  2016-09       Impact factor: 1.011

6.  Role of WB-MR/DWIBS compared to (18)F-FDG PET/CT in the therapy response assessment of lymphoma.

Authors:  Nicola Maggialetti; Cristina Ferrari; Carla Minoia; Artor Niccoli Asabella; Michele Ficco; Giacomo Loseto; Giacomina De Tullio; Vincenza de Fazio; Angela Calabrese; Attilio Guarini; Giuseppe Rubini; Luca Brunese
Journal:  Radiol Med       Date:  2015-09-09       Impact factor: 3.469

7.  Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.

Authors:  Diponkar Banerjee
Journal:  Adv Hematol       Date:  2011-01-18

8.  A Polymorphism Located Near PMAIP1/Noxa Gene Influences Susceptibility to Hodgkin Lymphoma Development in South India

Authors:  Dimpal N Thakkar; Sunitha Kodidela; Selvarajan Sandhiya; Biswajit Dubashi; Steven Aibor Dkhar
Journal:  Asian Pac J Cancer Prev       Date:  2017-09-27

9.  Time Trends in Rates of Hodgkin Lymphoma Histologic Subtypes: True Incidence Changes or Evolving Diagnostic Practice?

Authors:  Sally L Glaser; Christina A Clarke; Theresa H M Keegan; Ellen T Chang; Dennis D Weisenburger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-07-27       Impact factor: 4.090

10.  Concurrent malignant melanoma and cutaneous involvement by classical Hodgkin lymphoma (CHL) in a 63 year-old man.

Authors:  Alejandro A Gru; Dongsi Lu
Journal:  Diagn Pathol       Date:  2013-08-09       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.